Brief: LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need For Diabetes Screening And Monitoring
26/05/2022 12:41
May 26 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX HBA1C TEST ACHIEVES CE MARK, ADDRESSES GROWING
GLOBAL
NEED FOR DIABETES SCREENING AND MONITORING WITH ITS
NEXT-GENERATION POINT OF CARE DIAGNOSTIC PLATFORM
Source text for Eikon: ID:nPn9pV28Ba
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing